Core Viewpoint - Johnson & Johnson (JNJ) is expected to report quarterly earnings of $2.66 per share, reflecting a 5.7% decline year-over-year, while revenues are forecasted to increase by 1.5% to $22.79 billion [1] Earnings Estimates - The consensus EPS estimate has been revised 0.5% higher in the last 30 days, indicating analysts' positive reassessment of the company's performance [1][2] Revenue Estimates by Segment - MedTech Total Sales: Estimated at $8.25 billion, indicating a year-over-year increase of 3.7% [3] - Innovative Medicine Worldwide Sales: Expected to reach $14.55 billion, reflecting a 0.4% increase from the prior year [4] - Innovative Medicine Immunology Sales: Forecasted at $3.86 billion, showing an 18.2% decline year-over-year [4] - Innovative Medicine Neuroscience Sales: Anticipated to be $1.99 billion, representing an 11.6% increase [4] Specific Product Sales Estimates - Oncology CARVYKTI Sales: Projected at $409.72 million, indicating a significant increase of 120.3% from the previous year [5] - Neuroscience SPRAVATO Sales: Expected to be $371.85 million, reflecting a 37.2% increase [5] - MedTech Cardiovascular ABIOMED Sales: Estimated at $423.95 million, showing an 11.9% increase [6] - MedTech Orthopaedics Hips US Sales: Projected at $269.05 million, indicating a 1.5% increase [7] Organic Sales Growth - Analysts predict an organic sales growth of 2.7%, down from 6.6% reported in the same quarter last year [8] Stock Performance - Johnson & Johnson shares have increased by 0.7% over the past month, compared to a 4.1% increase in the Zacks S&P 500 composite [8]
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics